Genprex Inc Market Cap ($1.89 Million)
Market Cap & Net Worth: Genprex Inc (GNPX)
Genprex Inc market cap. Genprex Inc (NASDAQ:GNPX) has a market capitalization of $1.89 Million ($1.89 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30090 globally and #6143 in its home market, demonstrating a 27.62% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Genprex Inc's stock price $2.31 by its total outstanding shares 819709 (819.71K). Also see Genprex Inc operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Genprex Inc Market Cap History (2018–2026)
Genprex Inc market cap history from 2018 to 2026. Data shows change from $36.07 Million to $1.89 Million (-40.02% CAGR). Check latest Genprex Inc stock price today for real-time trading data and today's change.
Index Memberships
Genprex Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #874 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2787 of 3165 |
Weight: Genprex Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Genprex Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Genprex Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Genprex Inc net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of GNPX by Market Capitalization
Companies near Genprex Inc in the global market cap rankings as of November 4, 2026. Also see GNPX total asset value for a full breakdown of the balance sheet.
Key companies related to Genprex Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Genprex Inc (2018–2026)
Market capitalization of Genprex Inc from 2018 to today. Between 2018 and today, Genprex Inc's market cap moved from $36.07 Million to $ 1.89 Million, with a yearly change of -40.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.89 Million | +32.00% |
| 2025 | $1.43 Million | +105.50% |
| 2024 | $698.06K | -90.74% |
| 2023 | $7.54 Million | -84.14% |
| 2022 | $47.54 Million | +10.69% |
| 2021 | $42.95 Million | -68.43% |
| 2020 | $136.07 Million | +1196.88% |
| 2019 | $10.49 Million | -70.91% |
| 2018 | $36.07 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Genprex Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.89 Million USD |
| MoneyControl | $1.89 Million USD |
| MarketWatch | $1.89 Million USD |
| marketcap.company | $1.89 Million USD |
| Reuters | $1.89 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Genprex Inc
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing pla… Read more